Sarepta Therapeutics (SRPT) options active amid large share price sell off
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT)
July 21, 2025 6:55 AM EDTTD Cowen analyst Ritu Baral reiterated a Hold rating and $28.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)
The analyst comments "Lack of proactive disclosure in recent rh74 GTx-related death undermines credibility with investors. Last week, at the start of the International LGMD Conference (Orlando), unsubstantiated media reports disclosed a 51 yr old pt in the Ph1/2 trial of rh74-based GTx SRP-9004 (for LGMD Type 2D) died 11 wks post-Tx... More
BofA Securities Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
July 21, 2025 6:03 AM EDTBofA Securities analyst Tazeen Ahmad reiterated a Neutral rating and $20.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "On Friday night, Sarepta (SRPT) reported that the company received an informal request from the Food and Drug Administration (FDA) to voluntarily halt all shipments of Elevidys. The company announced they plan... More
